

Special Issue

COVID-19 Disparities and Vaccine Equity

Message from the Guest Editors

The COVID-19 pandemic has significantly compounded health disparities in several minority populations across the world, further widening gaps in social, political, economic, and racial inequities. Despite the availability of effective vaccines developed against SARS-CoV-2, varying degrees of access and uptake among communities affected by historical and cultural trauma continue to adversely impact minority populations, leading to fractured and ineffective responses to COVID-19 mitigation efforts. This Special Issue intends to explore the dynamics of COVID-19 disparities in minority populations internationally and the impact of mitigation efforts, including vaccines, over the course of the pandemic. Topics of interest may include but are not limited to:

- vaccine hesitancy;
- attitudes and behaviors towards vaccines;
- COVID-19 disparities in infection and mortality disproportionately impacting racial/ethnic groups and/or other minorities;
- community-informed approaches, which may include CBPR methods, communication, and education;
- long-term health impacts of COVID-19.

Guest Editors

Dr. Alika K. Maunakea
Prof. Dr. Ruben Juarez
Dr. May Okihiro

Deadline for manuscript submissions

closed (31 July 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/125132

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).